Isofol Medical AB (OSTO:ISOFOL) Other Current Receivables: kr3.17 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ISOFOL Isofol Medical AB OSTO:ISOFOL
30 GF Score
Price kr0.78
! 2 Warning Signs
View Full Analysis

What is Isofol Medical AB Other Current Receivables?

Isofol Medical AB OSTO:ISOFOL +0.65% 30 Other Current Receivables is kr3.17 Mil as of Mar. 2026. GuruFocus rates OSTO:ISOFOL with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Isofol Medical AB's Other Current Receivables for the quarter that ended in Mar. 2026 was kr3.17 Mil.

Isofol Medical AB's quarterly Other Current Receivables declined from Sep. 2025 (kr3.35 Mil) to Dec. 2025 (kr1.07 Mil) but then increased from Dec. 2025 (kr1.07 Mil) to Mar. 2026 (kr3.17 Mil).

Isofol Medical AB's annual Other Current Receivables declined from Dec. 2023 (kr1.27 Mil) to Dec. 2024 (kr0.63 Mil) but then increased from Dec. 2024 (kr0.63 Mil) to Dec. 2025 (kr1.07 Mil).

Isofol Medical AB Other Current Receivables Related Terms

Isofol Medical AB Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Isofol Medical AB's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Isofol Medical AB Other Current Receivables Chart

Isofol Medical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.95 4.75 1.27 0.63 1.07

Isofol Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.38 3.46 3.35 1.07 3.17
OSTO:ISOFOL
30GF Score
Isofol Medical AB OSTO:ISOFOL
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Isofol Medical AB Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of kr3.17 Mil mean?
Isofol Medical AB (OSTO:ISOFOL) has a Other Current Receivables of kr3.17 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Isofol Medical AB and its competitors.
Is Isofol Medical AB's Other Current Receivables too high?
Isofol Medical AB's current Other Current Receivables is kr3.17 Mil. Overall, Isofol Medical AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Isofol Medical AB's Other Current Receivables compare to VRTX and REGN?
Isofol Medical AB's Other Current Receivables of kr3.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Isofol Medical AB and its competitors. Isofol Medical AB's current Other Current Receivables is kr3.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Isofol Medical AB stock overvalued right now?
Isofol Medical AB (OSTO:ISOFOL) has a current Other Current Receivables of kr3.17 Mil. The current Other Current Receivables is kr3.17 Mil. Isofol Medical AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Isofol Medical AB (OSTO:ISOFOL), the current Other Current Receivables is kr3.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Isofol Medical AB Business Description

Address Arvid Wallgrens Backe 20, Biotech Center, Gothenburg, SWE, SE-413 46
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.
30GF Score

Get the complete analysis for OSTO:ISOFOL

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.78
Price